Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.
1. A recombinant nonpathogenic Marek's Disease Virus (rMDV np ) comprising a first nucleic acid and a second nucleic acid inserted in a nonessential site in the rMDV np genome;
wherein the first nucleic acid comprises both a nucleotide sequence that encodes an Infectious Laryngotracheitis Virus glycoprotein D (ILTV gD) and a nucleotide sequence that encodes an Infectious Laryngotracheitis Virus glycoprotein I (ILTV gI);
wherein the second nucleic acid comprises a nucleotide sequence that encodes a Newcastle Disease Virus fusion protein (NDV F);
wherein the rMDV np genome comprises a US2 site and the nonessential site is the US2 site; and
wherein the rMDV np is not a recombinant avian herpesvirus comprising a Marek's disease virus (MDV) unique short viral genome region, a herpesvirus of turkeys (HVT) unique long viral genome region, and the repeat viral genome regions of the HVT.
2. The rMDV np of claim 1 , wherein the nucleotide sequence encoding the ILTV gD protein is operatively under the control of a first promoter, the nucleotide sequence encoding the ILTV gI protein is operatively under the control of a second promoter, and the nucleotide sequence encoding the NDV F protein is operatively under the control of a third promoter.
3. The rMDV np of claim 2 , wherein the first promoter, the second promoter, and the third promoter are all different.
4. The rMDV np of claim 3 , wherein the first promoter is the endogenous ILTV gD promoter and the second promoter is the endogenous ILTV gI promoter.
5. The rMDV np of claim 4 , wherein the third promoter is the human cytomegalovirus immediate early (hCMV IE) promoter.
6. The rMDV np of claim 5 , that is a recombinant herpesvirus of turkeys (rHVT).
7. A vaccine comprising the rMDV np of claim 1 .
8. The vaccine of claim 7 , wherein the rMDV np is a recombinant herpesvirus of turkeys (rHVT).
9. The vaccine of claim 8 , that further comprises an attenuated infectious bursal disease virus (IBDV).
10. The vaccine of claim 9 , wherein the attenuated IBDV is strain 89/03.
11. A recombinant nonpathogenic herpesvirus of turkeys (rHVT) comprising an HVT US2 site and a DNA molecule; wherein the DNA molecule is inserted into the HVT US2 site; and
wherein the DNA molecule comprises a nucleotide sequence that encodes an Infectious Laryngotracheitis Virus glycoprotein D (ILTV gD), a nucleotide sequence that encodes an Infectious Laryngotracheitis Virus glycoprotein I (ILTV gI), and a nucleotide sequence that encodes a Newcastle Disease Virus fusion protein (NDV F).
12. The rHVT of claim 11 , wherein the nucleotide sequence encoding the ILTV gD is operatively under the control of a first promoter, the nucleotide sequence encoding the ILTV gI is operatively under the control of a second promoter, and the nucleotide sequence encoding the NDV F is operatively under the control of a third promoter.
13. The rHVT of claim 12 , wherein the first promoter, the second promoter, and the third promoter are all different.
14. The rHVT of claim 13 , wherein the first promoter is the endogenous ILTV gD promoter and the second promoter is the endogenous ILTV gI promoter.
15. The rHVT of claim 14 , wherein the third promoter is the human cytomegalovirus immediate early (hCMV IE) promoter.
16. A vaccine comprising the rHVT of claim 15 .
17. The vaccine of claim 16 , that further comprises an attenuated infectious bursal disease virus (IBDV).
18. The vaccine of claim 17 , wherein the attenuated IBDV is strain 89/03.
19. A vaccine for aiding in the protection of a chicken comprising the rHVT of claim 11 .
20. A method for aiding in the protection of a chicken against ILTV comprising administering the vaccine of claim 16 .
21. A method for aiding in the protection of a chicken against ILTV comprising administering the vaccine of claim 7 .
22. The rHVT of claim 6 , wherein the first nucleic acid and the second nucleic acid are constructed as part of a DNA molecule that is inserted into the US2 site of the rHVT.
23. The rMDV np of claim 1 , wherein the first nucleic acid and the second nucleic acid are constructed as part of a DNA molecule that is inserted into the US2 site of the rMDV np .